Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · see citing works

Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis

Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976 · see citing works

Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine

Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258 · see citing works

Treatment-resistant depression and suicidality

Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256 · see citing works

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

Khin, N. A., Chen, Y., Yang, Y., Yang, P., & LAUGHREN, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 211 · see citing works

Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686 · see citing works

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · see citing works

Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway

Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 538 · see citing works

Depression

McCarron, R. M., Shapiro, B. B., Rawles, J., & Luo, J. S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202105180 · Cited by 500 · see citing works

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481 · see citing works

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418 · see citing works

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408 · see citing works

Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248 · see citing works

Depression and Heart Failure: The Lonely Comorbidity

Sbolli, M., Fiuzat, M., Cani, D., & O’Connor, C. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1865 · Cited by 240 · see citing works

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works

The role of dissociation in ketamine’s antidepressant effects

Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 221 · see citing works

Neocortical circuits in pain and pain relief

Tan, L. L., & Kuner, R. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00468-2 · Cited by 153 · see citing works

New and emerging approaches to treat psychiatric disorders

Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 147 · see citing works

Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134 · see citing works

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135 · see citing works

Long-term safety of ketamine and esketamine in treatment of depression

Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 123 · see citing works

The molecular pathophysiology of depression and the new therapeutics

Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122 · see citing works

The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence

McIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110 · see citing works

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108 · see citing works

Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies

Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 98 · see citing works

Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms

Wu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., & Kozorovitskiy, Y. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.022 · Cited by 93 · see citing works

Arketamine, a new rapid-acting antidepressant: A historical review and future directions

Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 92 · see citing works

GLP-1-directed NMDA receptor antagonism for obesity treatment

Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea‐Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J. T., Breum, A. W., et al. (2024) · Nature · doi:10.1038/s41586-024-07419-8 · Cited by 86 · see citing works

Generating comparative evidence on new drugs and devices after approval

Cipriani, A., Ioannidis, J. P. A., Rothwell, P. M., Glasziou, P., Li, T., Hernandez, A. F., Tomlinson, A., Simes, R. J., & Naci, H. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33177-0 · Cited by 87 · see citing works

Ketamine: Neuroprotective or Neurotoxic?

Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.672526 · Cited by 85 · see citing works

Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data

Efthimiou, O., Taipale, H. T., Raduà, J., Schneider‐Thoma, J., Pinzón-Espinosa, J., Ortuño, M., Vinkers, C. H., Mittendorfer‐Rutz, E., Cardoner, N., Tanskanen, A., et al. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00366-8 · Cited by 90 · see citing works

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators

Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82 · see citing works

Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors

Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 76 · see citing works

Generating comparative evidence on new drugs and devices before approval

Naci, H., Salcher‐Konrad, M., Kesselheim, A. S., Wieseler, B., Rochaix, L., Redberg, R. F., Salanti, G., Jackson, E., Garner, S. E., Stroup, T. S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33178-2 · Cited by 77 · see citing works

Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex

Wang, T., Weng, H., Zhou, H., Yang, Z., Tian, Z., Xi, B., & Li, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.072 · Cited by 80 · see citing works

Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 79 · see citing works

Effects of Esketamine on Postoperative Negative Emotions and Early Cognitive Disorders in Patients Undergoing Non-Cardiac Thoracic Surgery: A Randomized Controlled Trial

Luo, T., Deng, Z., Ren, Q., Mu, F., Zhang, Y., & Wang, H. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111447 · Cited by 75 · see citing works

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75 · see citing works

The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials

Hung, K., Kao, C., Ho, C., Hsing, C., Chang, Y.-J., Wang, L., Liao, S.-W., & Chen, I. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.03.012 · Cited by 82 · see citing works

Antidepressants for the treatment of depression in people with cancer

Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73 · see citing works

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency

Nikkheslat, N. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 71 · see citing works

Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology

Tian, F., Lewis, L. D., Zhou, D. W., Balanza, G. A., Paulk, A. C., Zelmann, R., Peled, N., Soper, D. J., Mercado, L. A. S. C., Peterfreund, R. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37463-3 · Cited by 66 · see citing works

Ketamine for Bipolar Depression: A Systematic Review

Bahji, A., Zarate, C. A., & Vázquez, G. H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 65 · see citing works

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

Glue, P., Loo, C. K. A., Fam, J., Lane, H., Young, A. H., Surman, P., BEDROC study investigators, Glozier, N., Fitzgerald, P. B., Liu, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03063-x · Cited by 65 · see citing works

A New Rapid-Acting Antidepressant

Krystal, J. H., Charney, D. S., & Duman, R. S. (2020) · Cell · doi:10.1016/j.cell.2020.02.033 · Cited by 63 · see citing works

GluN2A mediates ketamine-induced rapid antidepressant-like responses

Su, T., Lu, Y., Fu, C., Geng, Y., & Chen, Y. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01436-y · Cited by 63 · see citing works

Bridging Rapid and Sustained Antidepressant Effects of Ketamine

Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59 · see citing works

High Levels of Genetic Diversity within Nilo-Saharan Populations: Implications for Human Adaptation

Mulindwa, J., Noyes, H. A., Ilboudo, H., Pagani, L., Nyangiri, O. A., Kimuda, M. P., Ahouty, B., Asina, O. F., Ofon, E. A., Kamoto, K., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.07.007 · Cited by 59 · see citing works

Molecular mechanisms of psychiatric diseases

Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 58 · see citing works

Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization

Khoodoruth, M. A. S., Estudillo‐Guerra, M. A., Pacheco‐Barrios, K., Nyundo, A., Chapa-Koloffon, G., & Ouanes, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.886918 · Cited by 61 · see citing works

Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study

Yang, S. Q., Zhou, Y., Yang, S. T., Mao, X., Chen, L., Bai, Z.-H., Ping, A. Q., Xu, S. Y., Li, Q. W., Gao, K., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.007 · Cited by 58 · see citing works

Off-label uses of drugs for depression

Skånland, S. S., & Cieślar‐Pobuda, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172732 · Cited by 57 · see citing works

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56 · see citing works

Acupuncture Can Play an Antidepressant Role by Regulating the Intestinal Microbes and Neurotransmitters in a Rat Model of Depression

Li, P., Huang, W., Yan, Y., Cheng, W., Liu, S., Huang, Y., Chen, W., Chen, Y., Gao, Y., Lu, W., et al. (2021) · Medical Science Monitor · doi:10.12659/msm.929027 · Cited by 56 · see citing works

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000751 · Cited by 54 · see citing works

Alcohol Exposure Induces Depressive and Anxiety-like Behaviors via Activating Ferroptosis in Mice

Xu, C., Xiong, Q., Tian, X., Liu, W., Sun, B., Ru, Q., & Shu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213828 · Cited by 55 · see citing works

Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability

Levinstein, M. R., Carlton, M. L., Ianni, T. D., Ventriglia, E. N., Rizzo, A., Gomez, J. L., Budinich, R. C., Shaham, Y., Airan, R. D., Zarate, C. A., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.019 · Cited by 51 · see citing works

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis

Wang, S., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52 · see citing works

Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States

Ross, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51 · see citing works

Application of Ketamine in Pain Management and the Underlying Mechanism

Ma, X., Yan, J., & Jiang, H. (2023) · Pain Research and Management · doi:10.1155/2023/1928969 · Cited by 51 · see citing works

The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence

Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 50 · see citing works

Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine

Deyama, S., & Kaneda, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109335 · Cited by 46 · see citing works

The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach

Frank, D., Kuts, R., Tsenter, P., Gruenbaum, B., Grinshpun, Y., Zvenigorodsky, V., Shelef, I., Natanel, D., Brotfain, E., Zlotnik, A., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.035 · Cited by 44 · see citing works

Development of the Ketamine Side Effect Tool (KSET)

Short, B. L., Dong, V., Gálvez, V., Vulovic, V., Martin, D. M., Bayes, A. J., Zarate, C. A., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.120 · Cited by 47 · see citing works

Approval of esketamine for treatment-resistant depression

Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46 · see citing works

Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant

Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46 · see citing works

A bibliometric analysis of research on heart failure comorbid with depression from 2002 to 2021

Ying, H., Zhang, X., He, T., Feng, Q., Wang, R., Yang, L., & Duan, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13054 · Cited by 45 · see citing works

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review

Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2707 · Cited by 43 · see citing works

Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review

Ng, J., Rosenblat, J. D., Lui, L. M. W., Teopiz, K. M., Lee, Y. L., Lipsitz, O., Mansur, R. B., Rodrigues, N. B., Nasri, F., Gill, H., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.032 · Cited by 44 · see citing works

Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study

Ochs-Ross, R., Wajs, E., Daly, E., Zhang, Y., Lane, R., Lim, P., Drevets, W. C., Steffens, D. C., Sanacora, G., Jamieson, C., et al. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.09.014 · Cited by 43 · see citing works

Ascending‐Dose Study of Controlled‐Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability

Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N. A., & Hung, C. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1573 · Cited by 42 · see citing works

Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study

Brendle, M., Ahuja, S., Valle, M. D., Moore, C., Thielking, P. D., Malone, D. C., & Robison, R. J. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0149 · Cited by 42 · see citing works

The Rapidly Shifting Ketamine Landscape in the US

Wilkinson, S. T., Palamar, J. J., & Sanacora, G. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4945 · Cited by 42 · see citing works

Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm

Brymer, K. J., Johnston, J. N., Botterill, J. J., Romay-Tallón, R., Mitchell, M. A., Allen, J., Pinna, G., Caruncho, H. J., & Kalynchuk, L. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0609-z · Cited by 41 · see citing works

Mathematical modeling of the transmission of SARS-CoV-2—Evaluating the impact of isolation in São Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of CoViD-19

Yang, H. M., Lombardi, L. P., Castro, F. F. M., & Yang, A. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252271 · Cited by 41 · see citing works

Ketamine for the Treatment of Chronic Pain: A Comprehensive Review

Israel, J. E., Pierre, S. S., Ellis, E., Hanukaai, J. S., Noor, N., Varrassi, G., Wells, M., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25535 · Cited by 41 · see citing works

Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression

Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40 · see citing works

Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study

Araújo-de-Freitas, L., Santos‐Lima, C., Mendonça-Filho, E., Vieira, F., França, R. J. A. F., Magnavita, G. M., Cardoso, T. L., Correia‐Melo, F. S., Leal, G. C.-G., Jesus‐Nunes, A. P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114058 · Cited by 41 · see citing works

Inpatient suicide in psychiatric settings: Evaluation of current prevention measures

Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38 · see citing works

Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review

Souza‐Marques, B., Santos‐Lima, C., Araújo-de-Freitas, L., Vieira, F., Jesus‐Nunes, A. P., Quarantini, L. C., & Sampaio, A. S. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000312 · Cited by 39 · see citing works

A bibliometric analysis of research on (R)-ketamine from 2002 to 2021

He, T., Wang, D., Wu, Z., Huang, C., Xu, X., Xu, X., Liu, C., Hashimoto, K., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109207 · Cited by 35 · see citing works

Probabilistic Reinforcement Learning and Anhedonia

Kangas, B. D., Der‐Avakian, A., & Pizzagalli, D. A. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_349 · Cited by 34 · see citing works

Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment

Ng, J., Lui, L. M. W., Rosenblat, J. D., Teopiz, K. M., Lipsitz, O., Cha, D. S., Xiong, J., Nasri, F., Lee, Y. L., Kratiuk, K., et al. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05767-1 · Cited by 34 · see citing works

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Jones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 34 · see citing works

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity

Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 34 · see citing works

Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval

Trujillo, K. A., & Heller, C. Y. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112271 · Cited by 35 · see citing works

Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression

Gruenbaum, B. F., Kutz, R., Zlotnik, A. A., & Boyko, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320903951 · Cited by 32 · see citing works

Ketamine Treatment for Alcohol Use Disorder: A Systematic Review

Kelson, M., Burnett, J. M., Matthews, A., & Juneja, T. (2023) · Cureus · doi:10.7759/cureus.38498 · Cited by 34 · see citing works

Trends in Illicit Ketamine Seizures in the US From 2017 to 2022

Palamar, J. J., Wilkinson, S. T., Carr, T. H., Rutherford, C. G., & Cottler, L. B. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1423 · Cited by 32 · see citing works

Saikosaponin d downregulates microRNA-155 and upregulates FGF2 to improve depression-like behaviors in rats induced by unpredictable chronic mild stress by negatively regulating NF-κB

Chao, B., Huang, S., Pan, J., Zhang, Y., & Wang, Y. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.01.008 · Cited by 32 · see citing works

Ketamine for depression clinical issues

Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 32 · see citing works

Rapid acting antidepressants in the mTOR pathway: Current evidence

Athira, K. V., Mohan, A. S., & Chakravarty, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.022 · Cited by 33 · see citing works

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial

Domany, Y., & McCullumsmith, C. B. (2021) · Archives of Suicide Research · doi:10.1080/13811118.2021.1878078 · Cited by 32 · see citing works

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Kwaśny, A., Włodarczyk, A., Ogonowski, D., & Cubała, W. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040568 · Cited by 31 · see citing works

Metabolomics changes in brain-gut axis after unpredictable chronic mild stress

Xu, Q., Jiang, M. C., Gu, S., Zhang, X., Feng, G., Ma, X., Xu, S., Wu, E., Huang, J. H., & Wang, F. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05958-w · Cited by 31 · see citing works

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849758 · Cited by 31 · see citing works

Saikosaponin D exerts antidepressant effect by regulating Homer1-mGluR5 and mTOR signaling in a rat model of chronic unpredictable mild stress

Liu, C., Chen, J., Liu, Y., Zhou, X., Zhang, M., Jiang, Y.-M., Ma, Q., Xue, Z., Zhao, Z., Li, X., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00621-8 · Cited by 33 · see citing works

Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection

Wang, S., Bian, L.-H., Yin, Y., & Guo, J. (2022) · Brain Sciences · doi:10.3390/brainsci12101329 · Cited by 31 · see citing works

The trouble with antidepressants: why the evidence overplays benefits and underplays risks - an essay by John B Warren

Warren, J. B. (2020) · BMJ · doi:10.1136/bmj.m3200 · Cited by 30 · see citing works

Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression

Jha, M. K., Wilkinson, S. T., Krishnan, K., Collins, K. A., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M. I., Aloysi, A. S., Asghar‐Ali, A. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17786 · Cited by 30 · see citing works

S100A10 and its binding partners in depression and antidepressant actions

Chen, M. X., Oh, Y., & Kim, Y. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.953066 · Cited by 32 · see citing works

Acupuncture may play a key role in anti-depression through various mechanisms in depression

Li, P., Zhao, J., Wei, X., Luo, L., Chu, Y., Zhang, T., Zhu, A., & Yan, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00990-2 · Cited by 32 · see citing works

Influence of formulation and route of administration on ketamine’s safety and tolerability: systematic review

Glue, P., Russell, B., & Medlicott, N. J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03047-z · Cited by 29 · see citing works

A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action

Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 28 · see citing works

Esketamine nasal spray offers rapid improvement in treatment‐resistant depression

(2019) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30468

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156 · see citing works

Esketamine: the first glutamatergic drug for the management of treatment- resistant depression

Musazzi, L. (2020) · doi:10.36118/pharmadvances.03.2020.02 · Cited by 1 · see citing works

Esketamine Approved for Refractory Depression

D’Arrigo, T. (2019) · Psychiatric News · doi:10.1176/appi.pn.2019.4a28

Esketamine for treatment resistant depression

Jauhar, S., & Morrison, P. (2019) · BMJ · doi:10.1136/bmj.l5572 · Cited by 40 · see citing works